| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2017-12-19 |
Five Prime Therapeutics (USA - CA) Zai Lab (China) |
FPA144 (bemarituzumab) |
tumors that overexpress FGFR2b, including gastric and gastro-esophageal junction cancer |
licencing |
Cancer - Oncology |
Licensing agreement |
| 2017-12-18 |
Ultragenyx Pharmaceutical (USA - CA) Novartis (Switzerland) |
Rare Pediatric Disease Priority Review Voucher (PPRV) |
|
commercialisation |
Rare diseases - Genetic diseases |
Commercialisation agreement |
| 2017-12-18 |
Autifony Therapeutics (UK) Boehringer Ingelheim (Germany) |
- Kv3.1/3.2 positive modulator platform including AUT00206
|
schizophrenia, hearing disorders, orphan CNS disorders including fragile X syndrome |
|
CNS diseases - Otorhinolaryngology - Psychiatric diseases - Rare diseases |
Research agreement |
| 2017-12-18 |
Sensorion (France) Cochlear Limited (Australia) |
SENS-401 (R-azasetron besylate) in combination with cochlear implants |
|
collaboration - licensing |
Otorhinolaryngology |
Collaboration agreement |
| 2017-12-18 |
Oxford Genetics (UK) MeiraGTx (USA - NY) |
novel adeno-associated virus (AAV) vectors, packaging and producer cell lines |
|
development - manufacturing - production |
Rare diseases - Genetic diseases - Technology - Services |
Development agreement |
| 2017-12-17 |
Idorsia (Switzerland) Roche (Switzerland) |
|
|
research - development - R&D |
Cancer - Oncology |
Research agreement |
| 2017-12-15 |
Genethon (France) Orchard Therapeutics (UK) Yposkesi (France) |
- G1XCGD lentiviral vector (autologous haematopoietic cells genetically modified with a lentiviral vector containing the human gp91(phox) gene)
|
X-linked chronic granulomatous disease (X-CGD) |
research - development - licensing |
Rare diseases - Genetic diseases |
Licensing agreement |
| 2017-12-15 |
Mesoblast (Australia) Tigenix (Belgium) |
Cx601 (adipose derived allogeneic stem cell therapy) |
|
licensing |
|
Licensing agreement |
| 2017-12-14 |
Pharmaxis (Australia) Synairgen (UK) |
selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) |
idiopathic pulmonary fibrosis |
R&D - research |
Lung diseases - Respiratory diseases - Rare diseases |
R&D agreement |
| 2017-12-14 |
Teva Pharmaceutical (Israel) |
|
|
restructuring |
|
Restructuring |
| 2017-12-14 |
Samsung Medical Center (Republic of Korea) A*STAR’s Genome Institute of Singapore (GIS) (Singapore) Institute of Molecular and Cell Biology (IMCB) (Singapore) National Cancer Centre Singapore (NCCS) (Singapore) National University of Singapore (NUS) (Singapore) |
|
hepatocellular carcinoma |
collaboration - research |
Cancer - Oncology |
Collaboration agreement |
| 2017-12-14 |
Asklepios BioPharmaceutical (USA - NC) Actus Therapeutics (USA - NC) |
|
Pompe disease |
establishment of a new subsidiary in the US |
Rare diseases - Genetic diseases - Metabolic diseases |
Establishment of a new subsidiary in the US |
| 2017-12-13 |
Evotec (Germany) Center for Regenerative Therapies TU Dresden (CRTD) (Germany) |
small molecule candidates for retinal diseases |
retinal diseases |
research |
Ophtalmological diseases |
Research agreement |
| 2017-12-13 |
Audentes Therapeutics (USA - CA) |
|
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2017-12-12 |
CRISPR Therapeutics (Switzerland - UK) Vertex Pharmaceuticals (USA - MA) |
CRISPR’s gene editing technology, known as CRISPR-Cas9, CTX001 |
cystic fibrosis, hemoglobinopathies, including sickle cell disease |
R&D - research - development |
Rare diseases - Genetic diseases - Hematological diseases |
R&D agreement |
| 2017-12-12 |
Chugai Pharmaceutical (Japan) |
chief executive officer |
|
nomination |
Cancer - Oncology - Immunological diseases |
Nomination |
| 2017-12-12 |
Allergy Therapeutics (UK) Ergomed (UK) |
three OralVac immunotherapy products |
grass pollen allergy, tree pollen allergy, house dust mite allergy |
development |
Allergic diseases - Immunological diseases - Respiratory diseases |
Development agreement |
| 2017-12-12 |
Eyevensys (France) |
chief executive officer |
|
nomination |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Nomination |
| 2017-12-11 |
Exscientia (UK) |
chairman of the board of directors |
|
nomination |
Technology - Services |
Nomination |
| 2017-12-10 |
Medivir (Sweden) Janssen Pharmaceuticals, a J&J company (USA - NJ) |
simeprevir |
hepatitis C |
|
Infectious diseases |
Termination of an agreement |
